Viabio

About Viabio

Viabio develops software for modeling and simulating the physical processes involved in 3D bioprinting, specifically focusing on enhancing the viability of bioprinted tissues and organs through AI-driven analysis. The platform addresses the challenge of ensuring the survival of bioprinted constructs by providing real-time adjustments and optimization based on critical construction parameters.

<problem> Ensuring the viability of bioprinted tissues and organs is a significant challenge due to the complex physical processes involved in 3D bioprinting. Current methods lack real-time adjustment and optimization capabilities, hindering the efficiency and scalability of bioprinting technology. </problem> <solution> Viabio offers a SaaS platform that models and simulates the physical processes within bioprinted constructs to enhance their viability. The software uses AI and mathematical modeling to analyze critical construction parameters and provide real-time adjustments. By optimizing the design of bioprinted tissues and organs, Viabio's technology aims to improve the efficiency and scalability of 3D bioprinting. The platform focuses on analyzing spheroids, with future plans to study organoids and various 3D bioprinting techniques. </solution> <features> - Software-as-a-Service (SaaS) platform for modeling physical processes inside printed organic structures - AI-driven analysis to optimize bioprinted tissue and organ design - Real-time adjustment of bioprinting processes using computer vision control - Modeling of bioprinting physics to enhance viability - Capability to load an STL model composed of spheroids and adjust structure parameters - Time distribution of cell necrosis score after calculations - Cloud-based calculations to save user resources and time </features> <target_audience> Viabio targets researchers, scientists, and biotech companies involved in 3D bioprinting, tissue engineering, and regenerative medicine. </target_audience> <revenue_model> Viabio operates on a Software-as-a-Service (SaaS) model, offering monthly or annual subscriptions, with pricing dependent on the functionality required by the end-user, and a per-click mode with a one-time cost. </revenue_model>

What does Viabio do?

Viabio develops software for modeling and simulating the physical processes involved in 3D bioprinting, specifically focusing on enhancing the viability of bioprinted tissues and organs through AI-driven analysis. The platform addresses the challenge of ensuring the survival of bioprinted constructs by providing real-time adjustments and optimization based on critical construction parameters.

Where is Viabio located?

Viabio is based in London, United Kingdom.

When was Viabio founded?

Viabio was founded in 2023.

Who founded Viabio?

Viabio was founded by Maksim Annikov.

  • Maksim Annikov - Founder
Location
London, United Kingdom
Founded
2023
Employees
4 employees
Looking for specific startups?
Try our free semantic startup search

Viabio

Score: 29/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Viabio develops software for modeling and simulating the physical processes involved in 3D bioprinting, specifically focusing on enhancing the viability of bioprinted tissues and organs through AI-driven analysis. The platform addresses the challenge of ensuring the survival of bioprinted constructs by providing real-time adjustments and optimization based on critical construction parameters.

viabio.site50+
Founded 2023 – London, United Kingdom

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (<5)

Maksim Annikov

Founder

Company Description

Problem

Ensuring the viability of bioprinted tissues and organs is a significant challenge due to the complex physical processes involved in 3D bioprinting. Current methods lack real-time adjustment and optimization capabilities, hindering the efficiency and scalability of bioprinting technology.

Solution

Viabio offers a SaaS platform that models and simulates the physical processes within bioprinted constructs to enhance their viability. The software uses AI and mathematical modeling to analyze critical construction parameters and provide real-time adjustments. By optimizing the design of bioprinted tissues and organs, Viabio's technology aims to improve the efficiency and scalability of 3D bioprinting. The platform focuses on analyzing spheroids, with future plans to study organoids and various 3D bioprinting techniques.

Features

Software-as-a-Service (SaaS) platform for modeling physical processes inside printed organic structures

AI-driven analysis to optimize bioprinted tissue and organ design

Real-time adjustment of bioprinting processes using computer vision control

Modeling of bioprinting physics to enhance viability

Capability to load an STL model composed of spheroids and adjust structure parameters

Time distribution of cell necrosis score after calculations

Cloud-based calculations to save user resources and time

Target Audience

Viabio targets researchers, scientists, and biotech companies involved in 3D bioprinting, tissue engineering, and regenerative medicine.

Revenue Model

Viabio operates on a Software-as-a-Service (SaaS) model, offering monthly or annual subscriptions, with pricing dependent on the functionality required by the end-user, and a per-click mode with a one-time cost.